Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Perenostobart · SRF-617

Monoclonal antibody · Inhibitor of CD39 (ENTPD1) (ENTPD1) · developed by Coherus Oncology

Phase 2 Most advanced trial (none active)

CHRS Developer

1 Registered trials

What is Perenostobart?

Perenostobart is a fully human monoclonal antibody that binds the cell surface ectonucleosidase CD39 (ENTPD1) and blocks its enzymatic activity. By preventing conversion of extracellular ATP to AMP and adenosine, it is intended to raise immunogenic ATP and lower immunosuppressive adenosine in the tumor microenvironment. It is being studied in metastatic castration-resistant prostate cancer and prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: SRF-617
Drug type: Monoclonal antibody
Targets: CD39 (ENTPD1) (ENTPD1)
Mechanism: Inhibitor of CD39 (ENTPD1) (ENTPD1)
Pathways: ATP-to-adenosine conversion, adenosine-mediated immunosuppression in the tumor microenvironment, T-cell and dendritic cell stimulation
Therapy area: Oncology
Developer: Coherus Oncology, Inc. (CHRS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: O84ZK2F68E

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05177770	Phase 2	Metastatic Castration-resistant Prostate Cancer	Terminated	CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-resistant Prostate CancerProstate Cancer

More from Coherus Oncology

Toripalimab FDA approved Casdozokitug Phase 2 CHS-0214 Phase 3 CHS-1000 Phase 1 Tagmokitug Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CHRS page.

Follow CHRS, the company behind Perenostobart

See CHRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CHRS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z